In our randomised , controlled , phase @ trial NeOAdjuvant Herceptin ( NOAH ) trial in women with HER@-positive locally advanced or inflammatory breast cancer , neoadjuvant trastuzumab significantly improved pathological complete response rate and event-free survival .